Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction [4]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 2, 2006, Pages 474-476

  De Willige, Shirley Uitte ^a   Doggen, C J M ^b   De Visser, M C H ^a   Bertina, R M ^a   Rosendaal, F R ^a,b  

^a Department of Hematology   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN GAMMA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTERY THROMBOSIS; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FIBRINOGEN BLOOD LEVEL; GENE FREQUENCY; GENE FUNCTION; HAPLOTYPE; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LETTER; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK ASSESSMENT; RISK REDUCTION; VEIN THROMBOSIS; BLOOD; CASE CONTROL STUDY; GENETICS; MALE; NETHERLANDS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; FIBRINOGEN; HAPLOTYPES; HUMANS; MALE; MYOCARDIAL INFARCTION; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 33645575760     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01716.x     Document Type: Letter

References (13)

1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 11-30.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
3. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
4. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: 836-44.
5. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
6. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen {gamma}′ levels. Blood 2005; 106: 4176-83.
7. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
8. Mannila MN, Eriksson P, Lundman P, Samnegard A, Boquist S, Ericsson CG, Tornvall P, Hamsten A, Silveira A. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005; 93: 570-7.
9. Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
10. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14: 143-9.
11. Nickerson D. SeattleSNPs. NHLBI Program for Genomic Applications. [WWW document] UW-FHCRC, Seattle, WA. Available at: http://pga.gs.washington.edu. (accessed 15 April 2003).
12. Doggen CJM, Bertina RM, Cats VM, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000; 110: 935-8.
13. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-22.